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Highlights 
 The post-PCV invasive disease potential of 25 pneumococcal serotypes was estimated. 
 The invasive disease potential of non-vaccine types, except 12F, are lower than 19A. 
 Age and disease presentation influence the invasive disease potential of serotypes. 
 Knowledge of invasive disease potential is valuable to assess and design vaccines. 
 Due to the diversity, surveillance of serotypes in carriage and IPD is critical. 
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Summary 
Objectives: Burden of pneumococcal disease depends on the prevalence and invasive disease potential of 
serotypes. We aimed to estimate the invasive disease potential of serotypes in children under 5 years of age by 
combining data from different settings with routine immunisation with pneumococcal conjugate vaccines 
(PCV). 
Methods: We conducted a systematic review, supplemented by unpublished data, to identify data on the 
frequency of pneumococcal serotypes in carriage and invasive pneumococcal disease (IPD). We estimated the 
invasive disease potential of serotypes as the ratio of IPD in relation to carriage (odds ratio and 95%CI) 
compared with 19A (reference serotype) by meta-analysis. We report results based on a random effects model 
for children aged 0–23, 24–29, and 0–59 months and by invasive clinical syndromes. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
3 
 
Results: In comparison with 19A, serotypes 1, 7F, and 12F had a significantly higher invasive disease 
potential in children aged 0–23 and 0–59 months for all IPD and clinical syndromes (OR>5). Several non-
vaccine types (NVTs) (6C, 15A, 15BC, 16F, 23B, in these two age groups) had a lower invasive disease 
potential than 19A (OR 0·1−0·3). NVTs 8, 12F, 24F, and 33F were at the upper end of the invasiveness 
spectrum. 
Conclusions: There is substantial variation among pneumococcal serotypes in their potential to cause IPD and 
disease presentation, which is influenced by age and time after PCV introduction. Surveillance of IPD and 
carriage is critical to understand the expected effectiveness of current PCVs (in the longer term) and guide the 
development of future vaccines. 
Keywords 
Streptococcus pneumoniae; serotype; invasive disease potential; pneumococcal conjugate vaccine; meta-
analysis 
 
 
 
Introduction 
 Current pneumococcal conjugate vaccines (PCVs) protect against 10 to 13 serotypes (VT) (1, 4, 5, 
6B, 7F, 9V, 14, 18C, 19F, 23F (PCV10), plus 3, 6A, 19A (additional in PCV13) of the 97 different serotypes 
identified to date.
1
 Widespread and routine use of PCVs among children has resulted in alterations in carriage 
and disease due to shift in the distribution of pneumococcal serotypes. An analysis of 21 large surveillance 
systems in populations after the introduction of PCV7 in routine immunisation programmes demonstrated that 
while there was an overall and sustained decrease in childhood invasive pneumococcal disease (IPD), disease 
due to non-vaccine serotypes (NVT) had increased in all age groups.
2
 Additionally, replacement of VT with 
NVT in nasopharyngeal colonisation in both vaccinated children and unvaccinated populations has resulted in 
a small or no change of overall S. pneumoniae carriage prevalence in different settings globally.
3
 The effect of 
increases in prevalence of NVT nasopharyngeal carriage on childhood IPD and the contribution of specific 
serotypes to invasive disease in the long run remains uncertain. Since nasopharyngeal colonisation is a key 
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prerequisite for pneumococcal disease, the extent of serotype replacement in IPD is likely to be influenced by 
colonisation with NVT with low or high invasive disease potential.
3
 
 S. pneumoniae serotypes differ in their potential to cause IPD. In a meta-analysis of 7 datasets from 
the pre-PCV era,
4
 serogroups 1, 5 and 7 were associated with a higher invasive disease potential among 
children in relation to 14, the most frequent disease-causing type during this period. Those associated with a 
lower invasive disease potential included 3, 6A, and 15. Several studies have also found varying levels of 
invasive disease potential among serotypes.
5
 After routine use of PCV7, serotype 19A emerged as the most 
frequent serotype in childhood IPD across industrialised settings.
3
 No predominant serotypes have emerged as 
yet post-PCV10 or PCV13 implementation, though this may occur in the future. Assessing the invasive 
disease potential of VT and NVTs in relation to predominant serotypes subsequent to the introduction of 
higher valent PCVs in diverse geographical settings with routine immunisation programmes can assist in 
understanding the future effectiveness of higher valent PCVs against childhood IPD. Thus, we aimed to 
estimate the invasive disease potential of S. pneumoniae serotypes in young children, by age and syndrome, 
by pooling data from different countries with routine use of PCV. 
Methods 
Sources of data 
We identified published studies by systematic searches of electronic databases: Medline, Embase, and 
Global Health (Ovid), Global Health Library (WPRO, EMRO, and SEA), Web of Science, and LILACs. 
Searches were conducted between October and November 2015 by two reviewers (EB, SD). Search strategies 
are available in appendix pp 2–4. Eligibility criteria are available in Box 1. 
We requested re-analysed or an extension of previously published serotype-specific IPD/carriage data 
for the years when PCV was available in each setting up to the year 2015 from investigators in 20 locations (3 
in North America, 12 in Europe, 4 in Africa and 1 in Latin America) who were invited to collaborate. If sites 
evaluated multiple serotypes for morphologically distinct colonies, investigators were asked to report each 
serotype for which individual children tested positive separately. Data were collected between October 2015 
and May 2016. A data collection template was developed and piloted before its final use. EB maintained files 
and communication with collaborators. Datathief (http://www.datathief.org/) was used to extract data from 
figures in published studies. Serotype data for IPD, meningitis, bacteraemia/sepsis, pneumonia, or other 
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syndromes were extracted or requested for three age groups (0–<12, 12–23, and 24–59 months). We did not 
re-distribute serotypes 6A and 6C and analysed 15BC as a single serotype.
6,7
 
Definitions 
We defined IPD as the identification of S. pneumoniae from a normally sterile site and carriage from 
nasopharyngeal specimens. PCV coverage was defined as the percentage of children from carriage studies 
who received their age-specific PCV recommended dose. Other definitions from settings with routine use of 
PCV were available and accepted, e.g. percentage of children who received their primary immunisation series 
by 12 months of age. Annual data on IPD, but not carriage, were available for all years in all datasets. In each 
setting, we considered the year following the introduction of PCV for which data on isolates in both IPD and 
carriage were available as the first year for analysis. Since the annual number of IPD isolates was low in some 
settings, we included data from all eligible years after the initial year. 
Data analysis 
Our primary objective was to develop overall estimates of the invasive disease potential of individual 
serotypes compared to the reference serotype among children. Since not all settings had IPD and carriage data 
for two key age groups (0–23 and 0–59 months), we developed two sets of data with strict criteria by age for 
our main analyses. The invasive disease potential for narrower age groups (0–23 and 24–59 months) and 
across 3 clinical syndromes were estimated as secondary outcomes. For these analyses we only included 
datasets that reported data for all categories. The individual contribution of each serotype to IPD or carriage in 
each combined dataset was estimated (box 1). We restricted our meta-analyses to serotypes representing at 
least 1% of IPD in our combined dataset for 0–59 months. The reference serotype was selected based on 
criteria used in the pre-PCV era:
4
 a) serotype identified in both IPD and carriage studies for all datasets, b) 
serotype was among the largest overall proportion in both IPD and carriage datasets, c) serotype was among 
top 5 in individual datasets.  
The metan command in Stata Version 13 (College Station, TX: StataCorp LP) was used to estimate 
serotype-specific invasive disease potential odds ratio (ORs) and 95% confidence intervals (CI) by comparing 
with the reference serotype
4
 (box 1). Serotype-specific meta-estimates are reported if carriage or IPD data for 
a specific serotype were reported in at least 3 datasets. We decided to use a random effects model 
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(DerSimonian & Laird method) for meta-analysis as we anticipated substantial heterogeneity in the included 
studies.
8
 We report the heterogeneity for each serotype included in the meta-analyses using the I
2
 where 
values of less than 25% indicate low heterogeneity, of 25% to 50% as moderate and above 50% as 
considerable heterogeneity.
29
 We applied a continuity correction of 0·005
10
 when there were zero cases in 
either of the outcomes to estimate the invasive disease potential for serotypes detected among carriers but not 
causing IPD (or vice-versa). We report 95% CIs estimates and for the main analyses we use a p-value <0.002 
to denote statistical significance when assessing differences between OR for individual serotypes and the 
reference serotype using the Bonferroni correction to address issues of multiple comparisons. Sensitivity 
analyses were conducted to explore the effect of differences across datasets on overall meta-estimates by 
restricting analysis to datasets with the following characteristics: a) ≥70% PCV coverage, b) low prevalence 
of HIV, c) industrialised country settings, d) case counts from years subsequent to introduction of a higher 
valent PCV (10/13), e) implementation of PCV10 or PCV13.  
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Results 
The PRISMA flowchart depicts the process to identify datasets eligible for analysis (figure 1). We 
included 13 datasets (9 included data provided by collaborators and 4 from published studies).
11-14
 Datasets 
were from settings with routine use of PCVs from Europe, North America, Latin America, and Africa. The 
characteristics of IPD and carriage studies are shown in Table 1. While age groups were similar for the IPD 
and carriage data in our meta-analyses, there are differences across sites as well as within individual settings. 
Across sites, carriage studies included cross-sectional surveys among children in the community or sampled at 
different type of health facilities (Table 1). Within individual sites, the geographical/racial overlay of carriage 
data and IPD data are not exact (e.g. individual cities and nationwide data, respectively). In these cases, we 
aimed to obtain the carriage and IPD data that best correlated in each site and assumed that the carriage data 
are representative of the entire country.  
Serotype distribution in IPD and carriage 
Table 2 shows the overall distribution of serotypes in the different datasets included in the meta-
analyses. The combined dataset for the post-PCV introduction period for children 0–59 months included 2,648 
IPD isolates and 15,931 pneumococci isolates from carriers. The leading IPD-causing serotypes in our 
combined datasets included PCV10/13 serotypes, except for serotypes 4 and 9V. Serotypes included in meta-
analysis accounted for 85·3% of all IPD cases in the combined dataset (of which 48·6% were PCV13 and 
36·8% non-PCV13) and 69·6% of carriers (21·7% PCV13 and 48·1% non-PCV13). Among children 0–23 
months, 2,677 IPD and 10,930 carriage isolates were examined. Serotypes analysed were associated with 
86·8% (46·0% PCV13 and 40·7% non-PCV13) of IPD and 70·2% (23·2% PCV13 and 47·1% non-PCV13) of 
carriers. PCV13-type 19A was selected as the reference serotype. The distribution of serotypes in IPD cases 
and carriers in the not included in meta-analysis is provided in appendix p 6.    
Invasive disease potential by age group 
Nine settings were included in the analyses for children aged 0−59 months. Figure 2 shows results 
from meta-analyses of the invasive disease potential (OR) as a continuum of invasive disease potential. 
Overall, significant differences in the meta-estimates of the invasive disease potential of serotypes were 
found. Among VTs, 1 and 7F were significantly more invasive than 19A (OR between 5−15). Conversely, the 
invasive disease potential for 6A, 6B, 19F, and 23F was significantly lower (OR between 0·3−0·4). The 
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invasive disease potential of other VTs (3, 5, 14, and 18C), at the upper end of the spectrum, was not 
significantly different from 19A. The invasive disease potential of NVT 12F was higher than 19A, 5·8 times 
higher in relation to 19A while for other NVTs (6C, 15A, 15BC, 16F, 22F, 23B), the invasive disease 
potential was significantly lower than 19A (ORs ranged between 0·1−0·6). Estimates for the remaining NVTs 
(8, 10B, 24F, 33F, 35B, 38) were not significantly different from that of 19A. Figure 2 shows that the invasive 
disease potential relative to 19A of NVTs 12F, 8, 33F, 24F, 22F, and 38 ranked higher than other NVTs in this 
age group.  
In sensitivity analyses, the point-estimates from the overall analysis for children 0−59 months 
remained similar for serotypes with high or low invasive disease potential in relation to 19A (appendix p 7). 
Heterogeneity was negligible to moderate for serotypes with a higher or lower invasive disease potential than 
19A, except for 12F, 15A, 15BC. Sensitivity analyses did not influence the heterogeneity for these meta-
estimates. The invasive disease potential of serotype 5 was significantly higher than 19A when analysis was 
restricted to data from settings with PCV coverage >70% or when considering data from years subsequent to 
the introduction of the higher PCV, for which, the heterogeneity in the meta-analysis was low or negligible. 
There was low heterogeneity in the estimate of invasive disease potential for 35B when analyses were 
restricted to settings with low HIV prevalence of industrialised settings. Restricting analysis to data for the 
period with current higher valent PCV did not change the point estimate for serotypes with lower invasive 
disease potential (6A, 6B, 22F, and 23F), but results were no longer significantly different to 19A.  
 The analyses of data for 0−23 months olds (11 settings) showed similar results as for the 0−59 months 
old children (figure 3). VTs 1 and 7F were more invasive (by 5 to 7 fold) compared to 19A, while 6A, 6B, 
19F, and 23F were significantly less invasive than 19A (OR ranged between 0·3−0·4). The invasive disease 
potential of other VTs (3, 5, 14, and 18C) was not significantly different from 19A. For NVTs, the invasive 
disease potential relative to 19A of 12F, was higher than 19A and ranked higher than other NVTs; while 
estimates for 15A, 15BC, 16F, 35B, 6C, and 23B were lower compared to 19A and ranked lower than other 
NVTs. The sensitivity analyses in this age group demonstrated similar patterns as in the 0−59 months. There 
was low to moderate heterogeneity for serotypes with a higher or lower invasive disease potential than 19A, 
except for serotypes 6A, 12F, 15BC, and 35B. Less heterogeneity was noted in the meta-estimate for 
serotypes 5 and 35B when analysis was restricted to data from settings with PCV coverage >70% and with 
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low HIV prevalence or industrialised, respectively. Inclusion of a PCV10 dataset in this age group did not 
impact the overall conclusion as results were similar to those when all datasets were considered (appendix pp 
8–9). 
Invasive disease potential by narrow age groups and clinical IPD syndromes 
For six settings, the serotype-specific invasive disease potential could be estimated for children 0–23 
and 24–59 months (table 1). The distribution of the meta-estimates for the invasive disease potential of 
individual serotypes is shown in appendix p 1. There was overlap of 95%CI for estimates of invasive disease 
potential with the reference type for most serotypes. Considering all meta-estimates of invasive disease, there 
was considerable heterogeneity for potential in 11 serotypes in the 0–23 months age groups. However, 
heterogeneity was negligible to moderate for most serotypes in the 24–59 months age group (except for 4 
serotypes: 5, 6A, 33F, NT) (appendix p 10). Though there was overlap of the wide 95% CIs, point estimates 
of individual serotypes for both age groups were largely in agreement in terms of magnitude as well as in 
direction of the OR in relation to 19A, with a few exceptions. The point estimate of serotypes’ invasive 
disease potential was 3−4 fold higher for serotypes 1 and 5 in the 24−59 months age group. The point 
estimates for serotypes 14 and 18C suggested a higher invasive disease potential than 19A in the 24−59 
months age group, despite a lower potential in children 0−23 months of age (appendix pp 1, 10). 
Five datasets provided serotype data from isolates for meningitis, bacteraemia/sepsis and pneumonia 
for children 0–59 months (table 1). Confidence intervals of meta-estimates of invasive disease potential for 
individual serotypes were wide and, for most of the serotypes these overlapped with the reference serotype. 
Considering all serotypes, heterogeneity of meta-estimates was generally low to moderate for most serotypes 
in bacteraemia/sepsis and meningitis cases, while considerable heterogeneity was noted when pooling 
invasive disease potential for pneumonia (appendix 11). Overall, point estimates of invasive disease potential 
for individual serotypes showed consistency in the direction of invasive disease potential in relation to 19A 
across syndromes, with a few exceptions (figure 4, appendix p 11). Meta-analyses of invasive disease 
potential and differences with the reference type by narrow age groups and by syndromes should be 
interpreted with caution due to a reduced number of datasets and small sample sizes per serotype.  
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Discussion 
Our study shows that estimates of invasive disease potential of non-PCV13 serotypes differ and were 
usually lower than that of 19A. Serotypes with an invasive disease potential similar to 19A were also 
identified. This comprehensive assessment of serotype-specific disease potential across different geographic 
locations informs our understanding of the invasive disease potential of NVTs and thereby the potential of 
current PCVs for the prevention of IPD in the longer term. 
In agreement with pre-PCV findings, we found that serotypes differ in their ability to cause IPD
4
. In 
our dataset, VTs 1 and 7F that are included in PCV10 and PCV13 were significantly more invasive than 19A 
in children aged 0−59 and 0−23 months. Additionally, we observed that 12F, a serotype currently not included 
in PCVs, had a high invasive disease potential (compared with 19A), which is consistent with other findings.
15
 
In 2015, 12F was identified as the lead cause of IPD due to NVT (19%) in children 0−23 months in 
Belgium.
16
 Increases in incidence of IPD associated with 12F have also been noted among adults and in 
association with antibiotic resistance in South Africa.
17
 Considering the observed ability of 19A to rapidly fill 
in the vacant niche after eradication of PCV7-types
18
 and non-significant differences in IPD potential of other 
types like 22F, 24F, and 33F, the possibility of an emerging role in IPD for these serotypes post-introduction 
of PCV10 and PCV13 cannot be excluded. Our results thus re-emphasise the need for ongoing surveillance of 
circulating pneumococcal strains, despite the fact that available PCVs cover the majority of currently 
identified highly invasive serotypes. 
Overall incidence of childhood IPD in settings with mature PCV programmes has decreased, even 
though replacement disease has been noted across settings.
2
 Our meta-estimates provide further insights into 
the phenomenon of limited serotype replacement in childhood IPD post-higher valent PCVs. Highly invasive 
disease strains in relation to 19A in this study, such as 1 and 12F are rarely detected in the nasopharynx by 
conventional culture and serotyping methods
13,19
 or are known to have cyclical fluctuations.
20,21
 Since serotype 
1 is covered by PCV10 and PCV13, we need to await whether serotype 12F will become dominant in the 
future in childhood IPD. While our results indicate that the relative invasiveness of serotypes is higher or 
lower than 19A, our meta-estimates should be considered in light of the level of heterogeneity. The 
heterogeneity identified for some NVTs in our meta-analysis can also be reflective of a fluctuating, by time 
and locality, invasive disease potential across settings included in the meta-analyses. Several factors may 
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contribute to this heterogeneity, including factors assessed in our sensitivity analyses but also differences in 
blood culture rates and antibiotic susceptibility patterns. It is also important to note that the true heterogeneity 
across studies is also influenced by differences in study designs, populations, etc. (Table1) and the true 
uncertainty in estimates of invasive disease potential is wider than those reported by confidence intervals. It is 
as yet unpredictable whether replacement by a particular NVT will reach a similar level as with 19A 
replacement disease post-PCV7; e.g. 35% of all IPD cases in young children in 2005 in the USA.
22
 Increasing 
trends of disease and drug resistance due to 15A, 23B, and 35B have recently been reported in Europe and the 
USA.
23-25
 Our meta-analyses indicate that the invasive disease potential of these serotypes in the settings 
represented in our study is at the lower end of spectrum of invasiveness, and that we need to await 
developments of these serotypes, that may also depend on setting, antibiotic resistance and co-morbidities, 
like HIV exposure.  
Our review also shows that there is a clear gap in the evidence base as the invasive disease potential 
of serotypes in low-income countries in Asia and Africa in the post-PCV era remains poorly described. In 
these regions, serotypes’ proportional contribution to childhood IPD differed from industrialised settings 
before the introduction of PCV.
26-28
 Following PCV10 introduction, strains with serotypes such as 2, 8, 10F, 
12A, 12F, 18A, 38, and 45 have recently been found to be highly invasive in South Asia.
29
 As serotype 
replacement in carriage continues to take place after PCV implementation, evidence suggests that circulation 
of a greater number of serotypes, some with high invasive disease potential, may be found in low-income 
countries. 
The risk of invasive disease by specific serotypes in different childhood age groups has not been 
clearly determined. From our meta-estimates, though with overlapping confidence intervals, serotype 1 and 5 
were likely to be about 3−4 times more invasive in children 24−59 months than in those less than 2 years, 
while 14 and 18C appeared to be more invasive in the younger age group compared than the older. In another 
study, a higher invasive disease capacity was observed for 13 out of 15 serotypes in children 0−23 months, 
compared with those aged 24−84 months,30 which suggested that the varying propensity of strains to cause 
IPD may contribute to decline in incidence with increasing age. Direct comparisons between our study and 
this study cannot be made, as methodologies and serotypes analysed differed (e.g. methods to estimate 
invasiveness and geographic/temporal representation). Nonetheless, agreements in findings that serotypes 
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vary in their capacity to cause IPD events by age groups is important for public health purposes. If 
replacement in carriage results in more carriage of serotypes with lower invasive disease potential, these 
serotypes may nevertheless act like opportunistic serotypes in individuals at high risk of IPD (e.g. elderly or 
with co-morbidities) and severe IPD outcomes. These groups may constitute a large part of the remaining 
burden of S. pneumoniae in the future, even though, the overall IPD burden in the whole population would be 
lower. Data from ongoing studies in South Africa indicate that the invasiveness of serotypes are likely to 
differ by immune status (e.g. by HIV status). Further research in other settings is needed to explore 
differences in invasive disease potential by different populations.  
Pneumococcal serotypes have also been shown to vary in their ability to cause particular clinical 
outcomes, such as case fatality or disease syndrome like empyema or meningitis.
31
 We estimated the disease 
potential of strains by three IPD syndromes in children. Compared with 19A, among meningitis and 
pneumonia a higher invasive disease potential was estimated for 12F. There is a paucity of reliable data 
describing relationships between specific serotypes and individual clinical syndromes. Nevertheless, several 
studies have shown that serotype 12F is associated with meningitis and has been documented indirectly from 
outbreaks to be hyper-invasive.
5,32
 Increases in cases of overall IPD and antibiotic non-susceptible serotype 
12F following PCV introduction have been recently reported in Israel and France. This increase was caused 
by a single clone expansion and 89% of 12F IPD cases were penicillin non-susceptible in Israel, suggesting 
the need to monitor the invasiveness of 12F.
33,34
 Similarly, although 24F was not significantly more invasive 
than 19A, it appeared to be prone to cause meningitis. Serotype 24F has emerged as the leading cause of 
pneumococcal meningitis in France after PCV13 introduction in children 0−23 months.35 In Norway, 24F 
showed an increase in incidence and clinical severity.
36
 Further studies are required to understand the 
epidemiology of individual serotypes on the burden of IPD from a clinical perspective to inform on new 
prevention strategies in the PCV era. 
Our study has several limitations. Firstly, we chose 19A as the reference type even though it is not 
included in PCV10. This serotype is likely to be prone to selective advantages due to high genetic diversity, 
clonal shifts, and antibiotic resistance.
37
 However, it was the only serotype present in all datasets and this 
enabled an estimation of ORs across multiple settings. The comparison with 19A represents 19A invasiveness 
mostly in population immunised. Our sensitivity analysis showed no impact on the study conclusion when 
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PCV10 dataset was excluded. Secondly, some of our serotype-specific estimates are affected by low numbers 
of cases and heterogeneity was noted. As the number of childhood IPD cases has decreased upon PCV use, 
estimates of invasive disease potential based on incidence rates (which were not available for this analysis), 
will be required. Furthermore, sampling of carriage cases differed across settings, where antibiotic use is 
likely to vary. As these limitations affect precision and the ability to detect significant differences, we 
conducted a wide range of sensitivity analyses and focused on describing estimates and their plausible range 
of values rather than conducting significance tests to avoid issues of multiple comparisons. However, we did 
not assess the impact of other factors on the estimates of invasiveness, such as role of rates of blood culturing 
or antibiotic use. As these factors are likely to vary across sites, their role on estimates of invasive disease 
potential and heterogeneity remains to be assessed. Biases leading to under or overestimation of invasive 
disease potential cannot be excluded. Our IPD data came from passive surveillance systems and carriage data 
usually from cross-sectional studies. These sources are vulnerable to reporting and ascertainment biases. 
However, it has been shown that cross-sectional data can be used reliably to examine invasive disease 
potential of capsular types.
15
 Changes to clinical practices and blood culturing in the post-PCV era could also 
lead to underestimation of the role of S. pneumoniae in particular in ambulatory cases of pneumonia or 
bacteraemia.
3
 Additionally, introduction of PCV would have likely changed the ratio of bacteraemic and non-
bacteraemic pneumonia (the proportion of latter having increased substantially post-PCV).
38
 The use of post-
PCV data only a few years after introduction for settings that have transitioned to PCV10/13 is also a source 
of bias since development of new equilibria after PCV introduction may take time and up to 6-16 years.
39
 
PCV immunisation is effective on decreasing IPD and colonisation for targeted serotypes, but replacement by 
NVT takes time which could have led to underestimation of the role of NVTs.  
Our study has several strengths including the wide geographical spread of the included settings and 
the supplementation of published literature with data from collaborators, which enabled serotype-specific 
analyses and minimised information biases. We also included long study periods to minimise risk of random 
error due to small sample sizes or outbreaks of serotypes causing IPD. We have presented analyses for a large 
number of serotypes, selected by their role in causing disease in various settings. Additionally, we provide 
results for various sensitivity analyses and report meta-estimates based on random effects model to address 
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issues of heterogeneity across studies. Limitations withstanding, this paper provides a comprehensive view of 
the invasive disease potential of S. pneumoniae serotypes causing childhood IPD post-PCV. 
Conclusion 
There is substantial variation among pneumococcal serotypes in invasive potential to cause IPD and 
disease presentation which is influenced by age and time after PCV introduction. This poses challenges to the 
design of the optimal composition of PCV in different settings. Because of the diversity of pneumococcal 
serotypes, surveillance of IPD and carriage is critical to understand the sustained effectiveness of current PCV 
products in the longer term and guide the development of future PCVs for use in specific settings. 
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Box 1: Eligibility criteria for databases with S. pneumoniae carriage and/or IPD serotype data  
 
 
 
 
 
 
 
 
Inclusion criteria 
 Observational studies (prospective, retrospective) published between 2000−2015 
 S. pneumoniae serotypes’ data are available from carriage and invasive disease studies among children 0−59 
months from similar population during similar periods. 
 Study population included children vaccinated with PCVs or from settings with wide-spread routine use of PCVs. 
For carriage, data had to be from healthy or not exclusively from severely sick children. 
 IPD was defined as the identification of a pneumococcus isolate from a normally sterile site (e.g. blood, 
cerebrospinal, pleural effusions, or joint fluid) 
 Exclusion criteria: 
 Study does not report data on S. pneumoniae serotypes or serotype-specific data are not reported for all carriage or 
IPD cases 
 Serotype data for either IPD or carriage are not available specifically for a period post−PCV introduction 
 Serotype data are from study populations exclusively of immunocompromised populations or data include adults 
 If data overlap with other publications exists, studies with the longest study period or larger sample size are to be 
included 
 Isolates were recovered to address a specific question and high risk of bias (e.g. rates of antimicrobial resistance, 
severe cases) 
 IPD and carriage serotype data are not from similar paediatric populations 
 Pneumococcus recovered from nasopharynx with a diagnosis of invasive disease used as a surrogate from a 
normally sterile site (IPD) 
 
Serotypes’ overall contributions to IPD or carriage in the combined dataset were estimated as described in the 
following equation using the 0−59 months as an example: IPDi = 
∑    
   
   
 
        
Where xij is the number of isolates in serotype i in study j, j is the index of settings, N is total number of isolates 
serotyped in the combined dataset 
Invasive disease potential (OR) was estimated using the following formula:  
   (
   
    
) = 
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Table 1: Characteristics of datasets included in meta-analysis 
 Carriage IPD  
Setting, year 
PCV7 and PCV10-
13 introduction 
Study design Study population Study period in 
meta-analysis 
Study design Case ascertainment Study period 
in meta-
analysis 
Analyses 
dataset 
included 
USA Alaska†, 
PCV7 2001, 
PCV13 2009/10 
Cross-sectional 
annual surveys 
Children at urban pediatric clinics and 
at households in rural Alaska villages. 
≥80% vaccination coverage in 
carriage studies. 
 
2002, 2003, 2004, 
2008, 2009, 2010, 
2011, 2012, 2013, 
2014 
Statewide 
surveillance by 
clinical laboratories. 
IPD is a reportable 
condition in Alaska 
Positive culture from a 
normally sterile site from 
Alaska residents. IPD cases 
from south east Alaska were 
also excluded so the IPD data 
better correlates with the 
carriage data 
2002 to 2014, 
inclusive 
0–59 
months, 0-23 
months, 
narrow age 
groups, 
syndromes 
USA Atlanta 
ABCs 
PCV7 2001, 
PCV13 2010‡ 
Cross-sectional 
survey 
Children 6–59 months of age 
residents of the study area and who 
sought medical care, regardless of 
presenting symptom at the 
emergency department 
2009 Jan/Aug Continuous active 
population-based 
surveillance 
Positive culture from a 
normally sterile site from the 
residents of the study area 
2008Jun/2009
May 
0–59 
months, 
USA Boston† 
PCV7 2000, 
PCV13 2010 
Cross-sectional 
surveys 
Children attending well-child or sick 
visits at primary care practices in 16 
(2003/04) and 8 (other study periods) 
communities during respiratory virus 
season  
2003Nov/04Apr, 
2006Oct/07Apr, 
2008OCt/09Apr, 
2010OCt/11Apr, 
2013Oct/14Apr 
Passive, 
prospective 
surveillance 
Positive culture from a 
normally sterile site in 
Massachusetts 
Oct-Sep in 
years 2003/04, 
2006/07, 
2008/09, 
2010/11, 
2013/14 
0-23 months 
USA Navajo 
PCV7 2000, 
PCV13 2010‡ 
Prospective 
longitudinal 
observational 
cohort  
Representative selection of 
nasopharyngeal samples from the 
861 first acquisition isolates  from a 
prospective longitudinal observational 
cohort study of children <5 years 
 
2006Mar-2008Mar Active surveillance 
of clinical 
microbiology 
laboratories  
Children <5 years of age who 
resided in the carriage cohort 
study communities, and who 
had an incident episode of IPD 
identified through active 
surveillance  
2006March to 
2008March 
0–59 
months, 
Colombia 
PCV7: 2009; 
PCV13  ‡ 
Cross-sectional 
survey 
Nasopharyngeal samples recovered 
at six urban areas of Bogotá from 
healthy children of 12 to 18 months of 
age, which were vaccinated with 
PCV7.  
2011Jun/Nov Passive, 
prospective 
surveillance  
Children ≤2 years of age 
diagnosed with IPD who were 
living in Bogotá through the 
National Surveillance 
Program*  
2010-201 0-23 months 
France 
PCV7: 2006; 
PCV13  2010 
Cross-sectional 
surveys 
300 healthy children aged 6–24 
months for well-baby visits among 90 
paediatricians. 
2008/09 and 2012/13 Prospective 
surveillance 
Cases reported from 400 
laboratories located in the 22 
regions of France  
2008/09 and 
2012/13 
0-23 months 
Israel† 
PCV7: 2009; 
PCV13  2010 
Prospective 
health-facility 
based 
surveillance. 
Collection of NP among healthy 
children visiting the paediatric 
emergency or maternal and child 
health centres for vaccination or 
regular check-up in Southern Israel 
2010, 2011, 2012, 
2013, 2014, 2015 
Prospective 
surveillance  
Positive culture from a 
normally blood or 
cerebrospinal fluid from the 
entire country 
2010, 2011, 
2012, 2013, 
2014, 2015 
0–59 
months, 0-23 
months, 
narrow age 
groups, 
syndromes 
Italy† 
PCV7: 2006; 
PCV13  2010 
Prospective, 
cross-sectional 
surveys 
PCV13-vaccinated healthy children in 
Milan, Lombardy, Italy 
Sep/Dec 2011, Jun 
2011, Sep12/Dec12 
Prospective 
surveillance system  
Positive culture from blood 
and/or cerebrospinal fluid 
Lombardy 
2011 to 2015, 
inclusive 
0–59 
months, 0-23 
months 
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 Carriage IPD  
Setting, year 
PCV7 and PCV10-
13 introduction 
Study design Study population Study period in 
meta-analysis 
Study design Case ascertainment Study period 
in meta-
analysis 
Analyses 
dataset 
included 
evaluated by 
home visits 
Netherlands†  
PCV7: 2006; 
PCV13  2011 
Prospective, 
cross-sectional 
surveys in two 
age-cohorts of 
healthy children 
vaccinated 
evaluated by 
home visits  
Child had to be vaccinated according 
to the national immunization 
schedule, the parents have to be 
willing and able to participate in the 
trial according to procedure. The child 
is either 11 or 24 months old (+/- 1-4 
weeks) in the Western region 
2009 Feb-Jul, 
2010/11 Sep-
March2012/13 Sep-
March 
Prospective 
surveillance 
Reference laboratory provided 
the IPD data from the same 
period and age group as 
carriage data, nationwide 
2009−14, 
inclusive 
0-23 
months** 
Norway†  
PCV7: 2006; 
PCV13 2011 
Cross-sectional 
surveys 
Children in daycare centres in and 
around Oslo. 
2006 Autumn, 2008 
Autumn, 2013 
Autumn, 20015 
Autumn 
Prospective 
surveillance 
Positive culture from a 
normally sterile site Reference 
Laboratory from the entire 
country 
2008 to 
2015(Nov), 
inclusive 
0–59 
months, 0-23 
months, 
narrow age 
groups, 
syndromes 
Spain† 
PCV7: 2001; 
PCV13  2011 
Prospective 
surveillance 
Healthy Children who attended 
University Hospital in Barcelona for 
minor surgical procedures in our 
hospital (i.e phimosis or dermatologic 
surgery) 
2004, 2005, 2006, 
2007, 2008, 2009, 
2010, 2014, 2015 
Prospective 
surveillance 
 
Presence of clinical findings of 
infection, together with the 
isolation by culture and/or 
DNA detection by real-time 
polymerase chain reaction 
(PCR) of S. pneumoniae in 
any usually sterile fluid at a 
University Hospital in 
Barcelona, Spain. 
2004 to 2015, 
inclusive 
0–59 
months, 0-23 
months, 
narrow age 
groups, 
syndromes 
UK†  
PCV7: 2006; 
PCV13  2010 
Cross-sectional 
surveys 
Children born between July 2006 and 
February 2009, recruited via the child 
health computer department and/or 
daycare facility. Children that had 
received PCV13, incomplete PCV7 
schedule, or with an acute respiratory 
infection were excluded. 
2010Nov/2011Sep20
14Feb/2015Aug 
Prospective 
surveillance 
IPD cases identified through 
10 laboratories sending 
isolates to Oxfordshire 
surveillance program 
2010–15 
inclusive 
0–59 
months, 0-23 
months, 
narrow age 
groups 
South Africa 
PCV7: 2009; 
PCV13  2011 
Cross-sectional 
surveys 
Well-baby clinics and ART clinics as 
part of a mother-infant pair study with 
concordant HIV status.  Excluded 
from study: Underlying illness that 
contraindicated an nasopharyngeal 
swab or discordant HIV status with 
mother 
2010May/2011Feb, 
2012May/2013Apr 
Passive, 
Population-based 
surveillance 
IPD cases were identified 
through the laboratory at Chris 
Hani Baragwanath Hospital, 
Soweto 
2010 to 2013, 
inclusive 
0–59 
months, 0-23 
months, 
narrow age 
groups, 
syndromes 
Notes: ABCs: Active Bacterial Core Surveillance, * Surveillance Networks System of Bacterial Agents Causing of Pneumonias and Meningitis † Includes data obtained from collaborators. 
‡Data included in analyses are for post-PCV7, but PCV13 has now been introduced in this setting. PCV coverage in the datasets ranged between 50% to >90%. **The variation within any 
group at the time of sampling was within +/- 1 month. Strains cultured from these children were likely to be acquired before they reached 24 months.
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Table 2: Serotype distribution and number of isolates included in meta-analyses 
Analysis Overall  By age  By clinical syndromes  
IPD definition Any IPD Any IPD Meningitis 
Bacteraemia 
Sepsis 
Pneumonia 
Age (months) 0−23 0−59 0−23 24−59 0−59 0−59 0−59 
Number of settings 11 9 6 6 5 5 5 
 Number of (n) IPD/Carriage Isolates (%)  
Total 2677/10930 2648/15931 1552/8214 862/6947 323/14408 719/14408 1133/14408 
PCV10 599/1158 (22·4/10·6) 767/1756 (29·0/11·0) (21·5/11·8) (42·6/10·8) (25.1/11.7) (23·4/11.7) (37·2/11.7) 
PCV13 not 10 657/1443 (24·5/13·5) 545/1825 (20·6/11·7) (21·4/11.7) (17·7/11·3) (13·3/11·6) (17·5/11·6) (23·9/11·6) 
NVT 1421/8329 (53·1/75·9) 1336/12350 (50·5/76·9) (57·1/76·4) (39·7/77·9) (61·7/78·4) (59·1/76·4) (38·8/76·4) 
1* 111/23 (4.1/0.2) 255/41 (9.6/0.3) 65/15 165/25 7/39 27/39 186/39 
3† 134/129 (5/1.2) 146/299 (5.5/1.9) 79/90 56/195 9/258 25/258 89/258 
5* 77/15 (2.9/0.1) 160/26 (6/0.2) 68/14 86/11 19/25 30/25 103/25 
6A† 48/358 (1.8/3.3) 52/434 (2/2.7) 31/267 21/159 9/426 18/426 26/426 
6B* 29/201 (1.1/1.8) 33/294 (1.2/1.8) 18/162 14/129 6/289 12/289 14/289 
6C 20/397 (0.7/3.6) 20/559 (0.8/3.5) 10/224 7/272 4/468 5/468 7/468 
7F* 189/45 (7.1/0.4) 124/83 (4.7/0.5) 70/25 40/57 12/74 32/74 53/74 
8 40/52 (1.5/0.5) 33/75 (1.2/0.5) 23/41 6/30 13/70 5/70 6/70 
10A 105/278 (3.9/2.5) 51/377 (1.9/2.4) 45/170 5/177 10/310 22/310 5/310 
10B 20/115 (0.7/1.1) 25/166 (0.9/1) 19/114 6/52 2/166 10/166 7/166 
12F 202/55 (7.5/0.5) 239/94 (9/0.6) 169/52 54/37 32/80 101/80 65/80 
14* 57/130 (2.1/1.2) 69/180 (2.6/1.1) 33/115 26/59 4/174 19/174 35/174 
15A 55/482 (2.1/4.4) 43/681 (1.6/4.3) 28/374 10/245 9/587 7/587 16/587 
15BC 154/1107 (5.7/10.1) 131/1503 (4.9/9.4) 93/844 31/613 22/1372 55/1372 25/1372 
16F 31/509 (1.2/4.7) 32/813 (1.2/5.1) 20/446 11/353 5/779 12/779 12/779 
18C* 21/41 (0.8/0.4) 19/66 (0.7/0.4) 7/34 11/32 4/66 11/66 3/66 
19A† 475/956 (17.7/8.7) 346/1092 (13.1/6.9) 222/607 76/429 25/1000 83/1000 156/1000 
19F* 63/404 (2.4/3.7) 47/602 (1.8/3.8) 38/340 4/248 13/586 19/586 9/586 
22F 87/238 (3.2/2.2) 76/401 (2.9/2.5) 46/174 17/207 8/350 19/350 17/350 
23B 34/562 (1.3/5.1) 42/873 (1.6/5.5) 21/411 15/421 9/756 13/756 5/756 
23F* 29/229 (1.1/2.1) 36/350 (1.4/2.2) 20/205 12/141 12/345 12/345 8/345 
24F 107/98 (4/0.9) 58/173 (2.2/1.1) 34/73 14/93 9/148 14/148 14/148 
33F 113/197 (4.2/1.8) 94/305 (3.5/1.9) 72/157 11/137 13/278 31/278 34/278 
35B 39/520 (1.5/4.8) 35/711 (1.3/4.5) 30/383 2/304 5/660 13/660 9/660 
38 36/103 (1.3/0.9) 39/202 (1.5/1.3) 28/86 7/109 1/181 18/181 8/181 
NT 48/431 (1.8/3.9) 56/727 (2.1/4.6) 42/356 14/328 9/663 6/663 37/663 
Notes: IPD: Invasive pneumococcal disease. n: number of cases, NVT: non-PCV13, *PCV10/13 and †PCV13 serotype. Data reported for “Other” clinical syndromes are not 
shown 
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Figure titles and legends 
 
 
Figure 1: PRIMSA flowchart  
Process to identify dataset to estimate S. pneumoniae serotypes invasive disease potential 
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Figure 2: Serotype-specific contribution to IPD, carriage, and invasive disease potential in children 0–59 months 
Serotypes are ranked by highest to lowest estimate of invasive disease potential. Bars depict overall contribution of each 
serotype to IPD and carriage in the combined dataset (%, left axis, N=9 settings). Dots show meta-estimates of serotype-
specific invasive disease potential (OR 95%CI, right axis on a log-scale, point estimate shown in boxes). Dotted black 
line: Reference line for invasive disease potential (19A; right axis). *PCV10/13 and †PCV13 serotype 
 
 
 
 
Figure 3: Serotype-specific contribution to IPD, carriage, and invasive disease potential in children 0–23 months 
Serotypes are ranked by highest to lowest estimate of invasive disease potential. Bars depict overall contribution of each 
serotype to IPD and carriage in the combined dataset (%, left axis, N=11 settings). Squares depict meta-estimates of 
serotype-specific invasive disease potential (OR 95%CI, right axis on a log-scale, point estimate shown in boxes). Dotted 
black line: Reference line for invasive disease potential (19A; right axis). *PCV10/13 and †PCV13 serotype 
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Figure 4: Serotype-specific invasive disease potential by syndromes in children 0−59 months 
Meta-estimates of serotypes’ invasive disease potential (OR 95%CI left axis on a log-scale) among cases of meningitis: 
grey solid line and circle, bacteraemia/sepsis: grey dotted line, and pneumonia: black solid line and dots. Dotted 
horizontal black line: Reference line for invasive disease potential (19A). *PCV10/13 and †PCV13 serotype 
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